Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

By A. Younes, N. Bartlett, J. Leonard, D. Kennedy, C. Lynch, E. Sievers, A. Forero-Torres. New England Journal of Medicine, 2010

1,331 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/67315d11bec6fce71080a86283a3255e294b89c5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Tsuchikama
2. Z. An
3. B. Pro
4. E. Sievers
5. R. Advani
6. P. Brice
7. J. Rosenblatt
8. A. Shustov

Citations in the corpus

• Antibody-drug conjugates: recent advances in conjugation and linker chemistries (2016, methodology): “, 2001), brentuximab vedotin (Adcetris) in 2011 for CD30-positive relapsed or refractory Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma (Younes et al., 2010), and trastuzumab emtansine (Kadcyla) in 2013 for HER2-positive breast cancer (LoRusso et al.”
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. (2012, result): “All rights reserved. objective responses were similar for the subset of patients with ALCL and the overall study population.19 Although conventional chemotherapy approaches are not curative, there is some evidence that autologous and allogeneic SCT may offer the opportunity for long-term benefit for”